Deferasirox increases BU blood concentrations

Bone Marrow Transplantation

Volumn 47, Issue 2, 2012, Pages 315-316

  Sweiss, K ^a   Patel, P ^a   Rondelli, D ^a,b  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; DEFERASIROX; FLUDARABINE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CANCER GROWTH; CASE REPORT; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG EFFECT; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRON OVERLOAD; LETTER; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; PREMEDICATION; PRIORITY JOURNAL; REFRACTORY ANEMIA; TREATMENT RESPONSE;

EID: 84857033026     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.75     Document Type: Letter

References (10)

1. Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Quigley J, Chen YH et al. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both? Bone Marrow Transplant 2008; 41: 935-940. (Pubitemid 351850496)
2. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclopho-sphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008; 14: 672-684. (Pubitemid 351664062)
3. Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008; 14: 220-228.
4. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055-3060. (Pubitemid 27172594)
5. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 477-485. (Pubitemid 35174821)
6. Beri R, Chunduri S, Sweiss K, Peace DJ, Mactal-Haaf C, Dobogai LC et al. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplant 2010; 45: 249-253.
7. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 2000; 39: 155-165.
8. Yang LP, Keam SJ, Keating GM. Deferasirox: a review of its use in the management of transfusional chronic iron overload. Drugs 2007; 67: 2211-2230. (Pubitemid 47557095)
9. Stumpf JL. Deferasirox. Am J Health Syst Pharm 2007; 64: 606-616. (Pubitemid 46481861)
10. Majhail NS, Lazarus HM, Burns LJ. Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant 2008; 41: 997-1003. (Pubitemid 352034174)